Shire
Also known as: Baxalta Innovations GmbH, now part of Shire | Baxalta now part of Shire | Baxalta US Inc., now part of Shire | Shire | SHIRE | Shire (Baxalta) | SHIRE DEV LLC | SHIRE HUMAN GENETIC | Shire Human Genetic Therapies, Inc. | Shire Inc, | Shire Inc. | Shire International GmbH | SHIRE LLC | SHIRE ORPHAN THERAP | Shire Orphan Therapies, LLC | SHIRE RICHWOOD
Highest phase reached
Phase 4
First clinical trial
May 1, 1995First marketed drug
Jan 1, 1986First NDA
Jun 19, 1990Last known activity
Jan 31, 2022
Timeline
1980s
- Jan 1, 1986
Shire— Founded
1990s
- Mar 26, 1997
Pharmavene— Acquired
- Aug 5, 1997
Richwood Pharmaceutical Company— Acquired
- Jul 27, 1999
Roberts Pharmaceutical— Acquired
2000s
- Feb 21, 2007
New River Pharmaceuticals— Acquired
- Jul 3, 2008
Jerini— Acquired
2010s
- Aug 3, 2010
Movetis— Acquired
- Jul 11, 2011
Advanced BioHealing— Acquired
- Apr 13, 2012
Pervasis Therapeutics, Inc— Acquired
- May 15, 2012
FerroKin BioSciences— Acquired
- Jan 8, 2013
Lotus Tissue Repair, Inc— Acquired
- Mar 12, 2013
Premacure AB— Acquired
- Mar 25, 2013
SARcode Bioscience— Acquired
- Jan 1, 2014
ViroPharma— Acquired
- May 1, 2014
Fibrotech— Acquired
- May 12, 2014
Lumena Pharmaceuticals— Acquired
- Jan 11, 2015
NPS— Acquired
- Jan 11, 2015
NPS Pharma— Acquired
- Feb 24, 2015
Meritage Pharma— Acquired
- Aug 3, 2015
Foresight Biotherapeutics— Acquired
- Jan 22, 2016
Dyax— Acquired
- Jun 3, 2016
Baxalta— Acquired
- Jul 1, 2016
tobramycin— Marketing Organization
- Sep 7, 2018
Sanaplasma AG— Acquired
- Dec 3, 2018
Takeda— Acquired By
- Dec 14, 2018
prucalopride succinate— NDA Organization
- Dec 14, 2018
prucalopride succinate— NDA Secondary Org
Drugs by trial phase (258 distinct, 756 trials)
Phase 4 (17 own, 43 via acquisition)
Phase 3 (20 own, 62 via acquisition)
Phase 2 (20 own, 44 via acquisition)
Phase 1 (13 own, 34 via acquisition)
Other trials (1 own, 4 via acquisition)
Indications
Approved for
- Angioedemas, Hereditary
- Arrhythmias, Cardiac
- Diarrhea
- Dry Eye Syndromes
- Duodenal Ulcer
- Edema
- Enteritis
- Hyperhidrosis
- Hypertension
- Hypotension, Orthostatic
- Kidney Failure, Chronic
- Mucopolysaccharidosis II
- Peptic Ulcer
- Thrombocythemia, Essential
- Thrombocytosis
- Thrombosis
- Urinary Bladder, Neurogenic
- Urinary Bladder, Overactive
Studied for
- Adenocarcinoma
- Adrenal Insufficiency
- Aggression
- Alagille Syndrome
- alpha 1-Antitrypsin Deficiency
- Alzheimer Disease
- Anemia
- Anemia, Sickle Cell
- Angioedema
- Angioedemas, Hereditary
- Anxiety Disorders
- Anxiety, Separation
- Arteriovenous Fistula
- Ataxia
- Attention Deficit and Disruptive Behavior Disorders
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Autistic Disorder
- beta-Thalassemia
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Binge-Eating Disorder
- Bipolar Disorder
- Brain Injuries
- Brain Injuries, Traumatic
- Bronchopulmonary Dysplasia
- Bulimia
- Calciphylaxis
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Carcinoma, Squamous Cell
- Cerebellar Ataxia
- Cholangiocarcinoma
- Cholangitis
- Cholangitis, Sclerosing
- Cholestasis
- Cholestasis, Intrahepatic
- Clostridium Infections
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Communicable Diseases
- Conjunctivitis
- Conjunctivitis, Allergic
- Conjunctivitis, Bacterial
- Conjunctivitis, Inclusion
- Conjunctivitis, Viral
- Constipation
- Crohn Disease
- Cytomegalovirus Infections
- Dementia
- Depression
- Depressive Disorder
- Disease
- Disruptive, Impulse Control, and Conduct Disorders
- Diverticulitis
- Dry Eye Syndromes
- Emphysema
- Eosinophilic Esophagitis
- Epidermolysis Bullosa
- Esophageal Squamous Cell Carcinoma
- Esophagitis
- Esophagitis, Peptic
- Eye Diseases
- Fabry Disease
- Familial Mediterranean Fever
- Fatigue
- Fatigue Syndrome, Chronic
- Fatty Liver
- Feeding and Eating Disorders
- Fibrosis
- Fistula
- Friedreich Ataxia
- Gastroesophageal Reflux
- Gaucher Disease
- Glaucoma
- Glaucoma, Open-Angle
- Glucose Intolerance
- Headache
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Hemosiderosis
- Hereditary Autoinflammatory Diseases
- Hirsutism
- Hyperkinesis
- Hyperphosphatemia
- Hypertension
- Hypocalcemia
- Hypoparathyroidism
- Hypotension
- Hypotension, Orthostatic
- Immunologic Deficiency Syndromes
- Infections
- Inflammation
- Iron Metabolism Disorders
- Iron Overload
- Irritable Bowel Syndrome
- Keratoconjunctivitis
Marketed drugs (37)
Subsidiaries (22 direct, 44 total across the full acquisition tree)
- Advanced BioHealing
- Baxalta
- Dyax
- FerroKin BioSciences
- Fibrotech
- Foresight Biotherapeutics
- Jerini
- Lotus Tissue Repair, Inc
- Lumena Pharmaceuticals
- Meritage Pharma
- Movetis
- New River Pharmaceuticals
- NPS
- NPS Pharma
- Pervasis Therapeutics, Inc
- Pharmavene
- Premacure AB
- Richwood Pharmaceutical Company
- Roberts Pharmaceutical
- Sanaplasma AG
- SARcode Bioscience
- ViroPharma
- AesRx L2
- Allelix L2
- American Hospital Supply L2
- Anaquest L2
- Apatech L2
- Archemix Corp. L2
- Ascot Pharmaceuticals L2
- Chatham Therapeutics L2
- DuoCort Pharma L2
- Enzon L2
- Flowsense L2
- Gambro L2
- Immuno AG L2
- Immuno US, Inc. L2
- Lev Pharmaceuticals L2
- Osterreichisches Institut fur Haemoderivate L2
- Pardes Biosciences, Inc. L2
- Pinnacle Pharmaceuticals L2
- Prism Research L2
- SuppreMol L2
- Target Quest, BV L2
- Arnar Stone L3
Recent trials (50)
- NCT04583007Lead sponsorN/A—
- NCT05067868Lead sponsorPhase 4Jan 31, 2022
- NCT05058391Lead sponsorPhase 4Jan 31, 2022
- NCT04985682Lead sponsorPhase 4Dec 30, 2021
- NCT04840667Lead sponsorPhase 3Nov 8, 2021
- NCT04840667Study directorPhase 3Nov 8, 2021
- NCT05059977CollaboratorPhase 1Oct 6, 2021
- NCT04683003CollaboratorPhase 3Apr 14, 2021
- NCT04440488Study directorPhase 4Mar 8, 2021
- NCT04440488Lead sponsorPhase 4Mar 8, 2021
- NCT04465396Lead sponsorPhase 1Mar 3, 2021
- NCT04444895Lead sponsorPhase 3Feb 1, 2021
- NCT04460105Lead sponsorPhase 1Oct 31, 2020
- NCT04278885CollaboratorPhase 2Oct 31, 2020
- NCT04578535Lead sponsorPhase 1Oct 27, 2020
Details
- Founded
- Hampshire, GB Jan 1, 1986
- First NDA
- Jun 19, 1990
- Last known activity
- Jan 31, 2022
Designations held
- Orphan drug
- Priority review
- Accelerated approval
Notes
https://pharmaphorum.com/views-and-analysis/a-history-of-shire/